Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

The science of gene therapy is enjoying a renaissance after ups and downs over the past 25 years. The heart of this field still largely relies on viral vector gene transfer systems that have evolved ...

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Viral Vector Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Viral Vector ...

WEST PALM BEACH, FL, Sept. 22, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTCID: FOXO) (“FOXO” or the “Company”), announces the closing of the acquisition of Vector Biosource Inc. (“Vector”).

TAMPA, FL and BLOOMINGTON, IN - (Sept. 8, 2021) - Vector Solutions, the leading provider of industry-focused software solutions for training, workforce management and risk communications, has acquired ...